Current SP appreciation, page-254

I’ll say 80/20 and maybe blushing a little though with such high level people in critical places of control I see the company ahead of the curve and zoning steadily in on ultimate success.
From Paul Rennie’s address at the AGM to a chat here and there with various interested parties I came away with very high confidence the drug will pass Phase 3 trials.
One should not hang on words but I have and I did hang on a few as totally sure the speakers I heard and spoke with have that sort of credibility to be taken seriously.
In fact the only reason I have 20% doubt is because I do not yet know the design of the trial? With the Good Doctor advising and assisting liaison with the FDA I am feeling very comfortable at this point to apply the above chance of success.
Plenty of time to pass as well before the ultimate presentation to the ASX of such a critical announcement, pretty relaxed on any risks with PAR atm.
At end this is my opinion only and DYOR is critical regards managing risk.